Navigation Links
Ocean Tomo Study Ranks Top 25 Most Inventive Illinois Companies in 2011 for Crain’s Chicago Business
Date:6/25/2012

Chicago, IL (PRWEB) June 25, 2012

Ocean Tomo, LLC, the Chicago-based Intellectual Capital Merchant Banc™ firm, announced the results of a proprietary study performed for Crain’s Chicago Business. The study, which ranks the 25 Illinois companies with the highest rated patent portfolios issued in 2011, was performed using the Ocean Tomo PatentRatings® system. This proprietary web-based platform (U.S. Patent No. 6,556,992) calculated a statistical measure of the relative quality of patents issued in 2011 to Illinois companies. Ranking companies based on this statistical quality metric is a proven means to identify future industry leaders. “The Ocean Tomo PatentRatings® study conducted for Crain’s Chicago Business suggests that Illinois has a broad diversity of established and emerging technology driven companies” explains James E. Malackowski, President and CEO of Ocean Tomo.

“Patents are one of the most reliable and critical indicators of a company’s strategic intent,” says Malackowski. “Furthermore, companies holding valuable patents in sufficient quantity are likely to shape industry direction and outperform their peers with respect to equity returns.” Malackowski cites the strong performance of the Ocean Tomo 300® Patent Index (NYSE Euronext: OTPAT) as support for the firm’s conclusions. "The ultimate value of a patent portfolio is not the rating or even licensing income; both are indirect effects” notes Malackowski. “The ultimate measure of value is the portfolio's effect on earnings and stock price. Our rating system has proven to be a forward looking indication of stock value with demonstrated out-performance as compared to the S&P 500 over a sustained period of time.”

To view the study methodology or see the expanded listing of the top 75 Illinois companies, visit http://www.OceanTomo.com/TopIllinoisCompanies.

About Ocean Tomo PatentRatings® Software System

Ocean Tomo PatentRatings® software system is the first proven, market-validated software platform for objectively assessing patent quality, relative valuation, and competitive trends for patents, patent portfolios, companies, and technology sectors. The PatentRatings® system provides customizable data solutions and delivers actionable data to companies, investors, bankers, attorneys and other intellectual property professionals and decision makers. The Ocean Tomo PatentRatings® system provides an unparalleled understanding of patent quality, technology implications, and strategic insight. Visit (http://www.OceanTomo.com/Ratings) for more information about data subscriptions or individual reports.

About Ocean Tomo
Established in 2003, Ocean Tomo, LLC, is the Intellectual Capital Merchant Banc™ firm. The company provides financial products and services related to Intellectual Property, including expert testimony, valuation, strategy, research, ratings, investments, risk management and transactions. Ocean Tomo assists clients – corporations, law firms, governments and institutional investors – in realizing Intellectual Capital Equity® value broadly defined.
Headquartered in Chicago, Ocean Tomo has offices in Greenwich, Houston, Orange County and San Francisco. Subsidiaries of Ocean Tomo include: Ocean Tomo Risk Management, LLC; Ocean Tomo Asset Management, LLC; OTI Data Networks, LLC; Patent Marking, LLC; and Ocean Tomo Capital, LLC – publisher of the Ocean Tomo 300® Patent Index family. Ocean Tomo is the founder of the Intellectual Property Exchange International (IPXI), Inc. as well as the exclusive licensee and distributor of the PatentRatings® system. For further information, visit http://www.OceanTomo.com.

Read the full story at http://www.prweb.com/releases/2012/6/prweb9638957.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. NSF CAREER grants support ocean energy, microforming, computer planning
2. Jellyfish inspires latest ocean-powered robot
3. Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
4. Positive Clinical Study Results for BSPs HyperQ Technology
5. 15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
6. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
7. Marshall study shows nanoparticles used as additives in diesel fuels can travel from lungs to liver
8. Clionsky Neuro Systems (CNS-Neuro) Announces Publication of Study Finding Elderly Patients Unable to Recognize Their Memory Loss
9. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
10. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
11. Singapore scientists lead human embryonic stem cell study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , ... March 22, 2017 , ... ... human tissue regeneration from small lab samples to full-size tissues, bones, even whole ... establish a vascular system that delivers blood deep into the developing tissue. ...
(Date:3/22/2017)... , March 22, 2017  UBM and the ... announce their extended partnership and the third annual Massachusetts ... by the 21 st Annual MassMEDIC Conference ... place May 3-4, 2017. MassMEDIC ... Association (ADVAMED) President and CEO, Scott Whitaker ...
(Date:3/22/2017)... 22, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... www.oramed.com ), a clinical-stage pharmaceutical company ... systems, announced today that Dr. Miriam Kidron ... presentation titled, "Oral Insulin for Diabetes Treatment: Bypassing ... Institute,s Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... York , March 22, 2017 ... largely fragmented, states a research report by Transparency Market ... Pfizer Inc., Amgen Inc., and AbbVie Inc., accounted for ... 2015. The prominent players in this market are focusing ... their product portfolio, which is likely to lead to ...
Breaking Biology Technology:
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... 7, 2017  Aware, Inc. (NASDAQ: AWRE ), ... financial results for its quarter and year ended December 31, ... 2016 was $3.9 million compared to $6.9 million in the ... of 2016 was $0.6 million compared to $2.6 million in ... quarter of 2016 was $0.5 million, or $0.02 per diluted ...
Breaking Biology News(10 mins):